Compare ENTX & FNWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENTX | FNWB |
|---|---|---|
| Founded | 2010 | 1923 |
| Country | Israel | United States |
| Employees | 22 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.2M | 93.1M |
| IPO Year | 2015 | 2012 |
| Metric | ENTX | FNWB |
|---|---|---|
| Price | $1.18 | $10.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $9.00 | ★ $13.50 |
| AVG Volume (30 Days) | ★ 85.4K | 28.9K |
| Earning Date | 05-14-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.70% |
| EPS Growth | N/A | ★ 36.00 |
| EPS | ★ 0.07 | N/A |
| Revenue | $42,000.00 | ★ $176,000.00 |
| Revenue This Year | N/A | $19.24 |
| Revenue Next Year | N/A | $8.90 |
| P/E Ratio | $17.43 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.91 | $7.05 |
| 52 Week High | $3.22 | $10.98 |
| Indicator | ENTX | FNWB |
|---|---|---|
| Relative Strength Index (RSI) | 44.85 | 65.44 |
| Support Level | $1.07 | $9.55 |
| Resistance Level | $1.37 | $10.98 |
| Average True Range (ATR) | 0.07 | 0.26 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 2.38 | 89.35 |
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It offers various products and services, such as commercial business loans, multi-family real estate loans, auto and consumer loans, transaction accounts, savings and money market accounts, online banking services, etc., focused on the lending, deposit, and money movement needs of individuals, businesses and nonprofit organizations. The Group's operations are mainly focused on serving various communities in Washington State, U.S. Substantially all of its income is derived from a diverse base of commercial, mortgage, and consumer lending activities and investments.